New York, NY -- (SBWIRE) -- 01/10/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Acasti Pharma Inc (NASDAQ:ACST), Peregrine Pharmaceuticals (NASDAQ:PPHM), Arca Biopharma Inc (NASDAQ:ABIO), Clean Diesel Technologies, Inc (NASDAQ:CDTI)
Acasti Pharma Inc (NASDAQ:ACST) showed a volume of 2.32 million shares by the end of last trade whereas the average volume of the stock remained 434,166.00 shares. The stock opened the session at $1.51 but then moved to $1.36. At that price, the stock showed a positive performance of 1.36%. Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Will ACST Get Buyers Even After The Recent Rally? Find Out Here
Peregrine Pharmaceuticals (NASDAQ:PPHM) opened the session at $1.55 and closed the session at $1.56. The stock showed a positive performance of 2.63% in previous trading session. Traded with volume of 2.27 million shares in the prior session and the average volume of the stock remained 2.16 million shares. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. For How Long PPHM will fight for Profitability? Read This Trend Analysis report
Arca Biopharma Inc (NASDAQ:ABIO) opened the session at $2.21 and closed the session at $2.06. The stock showed a negative performance of -8.85% in previous trading session. Traded with volume of 2.26 million shares in the prior session and the average volume of the stock remained 2.13 million shares. The beta of the stock remained 2.49. ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company's principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF).
Why Should Investors Buy ABIO After the Recent Fall? Just Go Here and Find Out
Clean Diesel Technologies, Inc (NASDAQ:CDTI) the stock advanced 21.58% and finished the session at $21.58. Traded with volume of 2.24 million shares in the prior session and the average volume of the stock remained 290,231.00 shares. The beta of the stock remained 2.18. Clean Diesel Technologies, Inc. is a global manufacturer and distributor of heavy duty diesels and light duty vehicle emissions control systems and products to automakers and retrofitters. The Company operates in two segments: Heavy Duty Diesel Systems division and Catalyst division. The Company's Heavy Duty Diesel Systems division specializes in the design and manufacture of verified exhaust emissions control solutions. Its Catalyst division produces catalyst formulations to reduce emissions from gasoline,
Will CDTI Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)